CoChat

Quantitative Systems Pharmacology Approaches for Immuno‐Oncology: Adding Virtual Patients to the Development Paradigm

Open access
Chelliah, Vijayalakshmi, Lazarou, Georgia, Bhatnagar, Sumit, Gibbs, John P., Nijsen, Marjoleen, Ray, Avijit, Stoll, Brian, Thompson, R. Adam, Gulati, Abhishek, Soukharev, Serguei, Yamada, Akihiro, Weddell, Jared, Sayama, Hiroyuki, Oishi, Masayo, Wittemer‐Rump, Sabine, Patel, Chirag, Niederalt, Christoph, Burghaus, Rolf, Scheerans, Christian, Lippert, Jörg, Kabilan, Senthil, Kareva, Irina, Belousova, Natalya, Rolfe, Alex, Zutshi, Anup, Chenel, Marylore, Venezia, Filippo, Fouliard, Sylvain, Oberwittler, Heike, Scholer‐Dahirel, Alix, Lelievre, Helene, Bottino, Dean, Collins, Sabrina C., Nguyen, Hoa Q., Wang, Haiqing, Yoneyama, Tomoki, Zhu, Andy Z.X., van der Graaf, Piet H., Kierzek, Andrzej M. · 2021 · Clinical Pharmacology & Therapeutics
Cited by 76

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Drug development in oncology commonly exploits the tools of molecular biology to gain therapeutic benefit through reprograming of cellular responses. In immuno‐oncology (IO) the aim is to direct the patient’s own immune system to fight cancer. After remarkable successes of antibodies targeting PD1/PD‐L1 and CTLA4 receptors in targeted patient populations, the focus of further development has shifted toward combination therapies. However, the current drug‐development approach of exploiting a vast number of possible combination targets and dosing regimens has proven to be challenging and is arguably inefficient. In particular, the unprecedented number of clinical trials testing different combinations may no longer be sustainable by the population of available patients. Further development in IO requires a step change in selection and validation of candidate therapies to decrease development attrition rate and limit the number of clinical trials. Quantitative systems pharmacology (QSP) proposes to tackle this challenge through mechanistic modeling and simulation. Compounds’ pharmacokinetics, target binding, and mechanisms of action as well as existing knowledge on the underlying tumor and immune system biology are described by quantitative, dynamic models aiming to predict clinical results for novel combinations. Here, we review the current QSP approaches, the legacy of mathematical models available to quantitative clinical pharmacologists describing interaction between tumor and immune system, and the recent development of IO QSP platform models. We argue that QSP and virtual patients can be integrated as a new tool in existing IO drug development approaches to increase the efficiency and effectiveness of the search for novel combination therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cpt.1987

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 76

Metadata

Authors
Chelliah, V., Lazarou, G., Bhatnagar, S., Gibbs, J. P., Nijsen, M., Ray, A., Stoll, B., Thompson, R. A., Gulati, A., Soukharev, S., Yamada, A., Weddell, J., Sayama, H., Oishi, M., Wittemer‐Rump, S., Patel, C., Niederalt, C., Burghaus, R., Scheerans, C., Lippert, J., Kabilan, S., Kareva, I., Belousova, N., Rolfe, A., Zutshi, A., Chenel, M., Venezia, F., Fouliard, S., Oberwittler, H., Scholer‐Dahirel, A., Lelievre, H., Bottino, D., Collins, S. C., Nguyen, H. Q., Wang, H., Yoneyama, T., Zhu, A. Z. X., van der Graaf, P. H., & Kierzek, A. M.
Venue
Clinical Pharmacology & Therapeutics
Publisher
Wiley
Published
2020-08-14
Volume
109
Issue
3
Pages
605-618
ISSN
  • 0009-9236 (ISSN-L)
  • 1532-6535
OpenAlex
W3042239416
Cited by
76
References
11
FWCI
2.97
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Quantitative Systems Pharmacology Approaches for Immuno‐Oncology: Adding Virtual Patients to the Development Paradigm. https://app.cochat.ai/papers/10.1002/cpt.1987
The paper
Chelliah, V., Lazarou, G., Bhatnagar, S., Gibbs, J. P., Nijsen, M., Ray, A., Stoll, B., Thompson, R. A., Gulati, A., Soukharev, S., Yamada, A., Weddell, J., Sayama, H., Oishi, M., Wittemer‐Rump, S., Patel, C., Niederalt, C., Burghaus, R., Scheerans, C., . . . Kierzek, A. M. (2021). Quantitative Systems Pharmacology Approaches for Immuno‐Oncology: Adding Virtual Patients to the Development Paradigm. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.1987

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.